# Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

> **NCT04490993** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Yahong Meditech Co., Ltd aka Asieris** · enrollment: 359 (actual)

## Conditions studied

- Non-muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** APL-1202 in combination with Epirubicin
- **DRUG:** Placebo in combination with Epirubicin

## Key facts

- **NCT ID:** NCT04490993
- **Lead sponsor:** Jiangsu Yahong Meditech Co., Ltd aka Asieris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-30
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-05-30
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04490993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04490993, "Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04490993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*